Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an update.
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 10,037 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities reflects routine capital management and slightly expands the company’s listed share base, with limited direct impact on its overall capital structure but maintaining flexibility for ongoing funding of operations and development activities.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australian-listed biopharmaceutical company (ASX: PAR) focused on developing and commercialising pharmaceutical therapies, operating within the life sciences sector and accessing capital through the Australian Securities Exchange.
Average Trading Volume: 885,603
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$143.1M
For an in-depth examination of PAR stock, go to TipRanks’ Overview page.